United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp. - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - tablet - 30 mg - isosorbide dinitrate tablets are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. the isosorbide dinitrate tablet is contraindicated in patients who are allergic to isdn or any of its other ingredients.

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate 30 mg - isosorbide dinitrate tablets, usp, are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. the isosorbide dinitrate tablet is contraindicated in patients who are allergic to isdn or any of its other ingredients

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - glycopyrrolate (unii: v92so9wp2i) (glycopyrrolate - unii:v92so9wp2i) - glycopyrrolate 1 mg - for use as adjunctive therapy in the treatment of peptic ulcer. glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.  glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - gemfibrozil (unii: q8x02027x3) (gemfibrozil - unii:q8x02027x3) - gemfibrozil 600 mg - gemfibrozil tablets, usp are indicated as adjunctive therapy to diet for: 1.  treatment of adult patients with very high elevations of serum triglyceride levels (types iv and v hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. patients who present such risk typically have serum triglycerides over 2000 mg/dl and have elevations of vldl-cholesterol as well as fasting chylomicrons (type v hyperlipidemia). subjects who consistently have total serum or plasma triglycerides below 1000 mg/dl are unlikely to present a risk of pancreatitis. gemfibrozil tablets, usp therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dl who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. it is recognized that some type iv patients with triglycerides under 1000 mg/dl may, through dietary or alcoholic indiscretion, convert to a type v pattern with massive triglyceride ele

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets are indicated for the suppressive treatment and treatments of acute attacks of malaria due to plasmodium vivax , p. malariae , p. ovale , and susceptible strains of p. falciparum . it is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. use of this drug is contraindicated (1) in the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, (2) in patients with known hypersensitivity to 4-aminoquinoline compounds, and (3) for long-term therapy in children.

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp. - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - promethazine hydrochloride injection is indicated for the following conditions: - amelioration of allergic reactions to blood or plasma. - in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. - for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. - for sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. - active treatment of motion sickness. - prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. - as an adjunct to analgesics for the control of postoperative pain. - preoperative, postoperative, and obstetric (during labor) sedation. - intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. promethazine hydroc

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - colchicine capsules are indicated for prophylaxis of gout flares in adults. limitations of use: the safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both p-glycoprotein and cyp3a4 inhibitors [see drug interactions (7)]. combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. patients with both renal and hepatic impairment should not be given colchicine capsules.  pregnancy category c . there are no adequate and well-controlled studies with colchicine capsules in pregnant women. colchicine crosses the human placenta. developmental studies in animals were not conducted with colchicine capsules, however published animal reproduct

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin injection is indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus , pseudomonas aeruginosa , serratia marcescens , escherichia coli , klebsiella pneumoniae , haemophilus influenzae , or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1) ]. levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible sta

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin for injection, usp is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. penumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - butalbital 50 mg - butalbital, aspirin, and caffeine tablets, usp are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of butalbital, aspirin, and caffeine in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. hypersensitivity to aspirin, caffeine, or barbiturates. patients with porphyria.